|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 54.44 CNY | +0.39% |
|
-6.46% | +23.45% |
| 05-19 | Gan & Lee Pharmaceuticals Completes First Patient Dosing in GZR102 Trial | MT |
| 04-25 | Gan & Lee Pharmaceuticals' 2024 Profit Jumps 81%, Operating Income Rises 17%; Shares Jump 10% | MT |
Main competitors
| Revenues (Y-1) | Net Margin (Y-1) | EBIT Margin (Y-1) | ROE (Y-1) | ROA (Y-1) | Leverage (Y-1) | ||
|---|---|---|---|---|---|---|---|
| 417M | 20.18% | 20.74% | 5.55% | 5.18% | -1x | ||
| 14.8B | 17.85% | 25.76% | 15.94% | 7.12% | 2.22x | ||
| 3.08B | 23.82% | 29.03% | 10.45% | 6.49% | 0.1x | ||
| 6.37B | 17.31% | 13.59% | 11.21% | 6.48% | 0.99x | ||
| 9.68B | 16.87% | 31.16% | 10.36% | 5.95% | 1.06x | ||
| 1.29B | -1% | -8.02% | -0.74% | -0.45% | -11.4x | ||
| 69.63M | 59.01% | 24.7% | 28.77% | 18.72% | -6.16x | ||
| 681M | -10.97% | -17.14% | -8.58% | -7.13% | 8.63x | ||
| 4.24B | 0.77% | 9.76% | 5.27% | 3.72% | -4.29x | ||
| 308M | 4.73% | 4.18% | 0.85% | - | -5.29x | ||
| 2.85B | 14.96% | 16.97% | 8.05% | 6.17% | -0.93x | ||
| 2.35B | 14.93% | 22.42% | 10.9% | 5.41% | 1.59x | ||
| 222M | -241.44% | -267.22% | 35.11% | -73.11% | -1.77x | ||
| 7.47B | 2.18% | 18.81% | 2.79% | 0.74% | 5.16x | ||
| 1.25B | 22.95% | 28.06% | 14.19% | 8.74% | 0.28x | ||
| 3.57B | 7.74% | 8.68% | 6.46% | 4.03% | 3.63x | ||
| 1.12B | 26.82% | 32.8% | 7.13% | 6% | -1.03x | ||
| 1.84B | 19.18% | 24.48% | 11.66% | - | - | ||
| 826M | 25.68% | 42.4% | 14.81% | 10.3% | -0.94x | ||
| Average | 3.29B | 2.19% | 3.22% | 10.01% | 0.84% | -0.51x | |
| Weighted average by Cap. | 6.01B | 10.9% | 12.79% | 11.04% | 3.97% | -0.03x |
- Stock Market
- Equities
- 603087 Stock
- Sector Gan & Lee Pharmaceuticals.
- Financial comparisons
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition